The effect analysis of atorvastatin combined with hybutimibe on blood lipids in patients with acute coronary syndrome undergoing interventional therapy
Objective To observe the effect of atorvastatin combined with hybutimibe on blood lipids in patients with acute coronary syndrome(ACS)undergoing interventional therapy.Methods A total of 68 patients with ACS undergoing interventional therapy were selected and were given atorvastatin combined with hybutimibe.The lipid indices[total cholesterol(TC),triglycerides(TG),high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),apolipoprotein B(ApoB),and non-high-density lipoprotein cholesterol(non-HDL-C)],hepatic and renal function indices[total bilirubin(TBIL),alanine aminotransferase(ALT),creatinine(Cr)],and markers of skeletal muscle injury[creatine kinase(CK)]were compared before and after treatment;the occurrence of adverse reactions after treatment was analyzed.Results At the 4th week of treatment,patients had TC of(3.37±0.51)mmol/L,LDL-C of(2.45±0.35)mmol/L,ApoB of(0.61±0.14)g/L,and non-HDL-C of(2.34±0.42)mmol/L,which were lower than(3.98±0.62)mmol/L,(2.84±0.44)mmol/L,(0.69±0.14)g/L,and(2.95±0.55)mmol/L at enrollment,and the differences were statistically significant(P<0.05),but there were no statistically significant differences in HDL-C and TG levels compared with those at enrollment(P>0.05).At the 8th week of treatment,the levels of TC,LDL-C and non-HDL-C were lower than those at the 4th week of treatment,and the differences were statistically significant(P<0.05),while the levels of ApoB,HDL-C and TG were not statistically significant compared with those at the 4th week of treatment(P>0.05).At the 4th week of treatment,patients had ALT of[28.0(16.6)]U/L and CK of(88.0±30.8)U/L,which were higher than[21.4(17.7)]and(76.8±25.0)U/L at enrollment,and the difference was statistically significant(P<0.05),and there was no significant difference in TBIL and Cr levels compared with those at enrollment(P>0.05).At the 8th week of treatment,ALT level was higher than that at the 4th week of treatment,and the difference was statistically significant(P<0.05),while TBIL,CK and Cr levels were not statistically significant compared with those at the 4th week of treatment(P>0.05).At the 4th week of treatment,1 patient withdrew due to severe elevation of ALT,which decreased to normal after discontinuing atorvastatin;1 patient had elevated CK,which decreased to normal at the 8th week after the dose of atorvastatin reduced to 10 mg/d once/d;all of them were considered to be the adverse reactions of atorvastatin.No other patients were discontinued due to abnormalities in liver function,creatine kinase,or renal function,and no other discontinuations due to adverse reactions occurred.Conclusion The combination of hybutimibe and atorvastatin can further reduce TC,LDL-C,ApoB,and non-HDL-C,and can be safely used in patients with ACS after interventional therapy,with minimal adverse reactions.
万方数据
维普
